Search Results - "Kaneko, Shun"

Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C by Nagata, Hiroko, Nakagawa, Mina, Asahina, Yasuhiro, Sato, Ayako, Asano, Yu, Tsunoda, Tomoyuki, Miyoshi, Masato, Kaneko, Shun, Otani, Satoshi, Kawai-Kitahata, Fukiko, Murakawa, Miyako, Nitta, Sayuri, Itsui, Yasuhiro, Azuma, Seishin, Kakinuma, Sei, Nouchi, Toshihiko, Sakai, Hideki, Tomita, Makoto, Watanabe, Mamoru

“…Graphical abstract…”
Get full text

Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan by Shimakami, Tetsuro, Setoyama, Hiroko, Oza, Noriko, Itakura, Jun, Kaneko, Shun, Korenaga, Masaaki, Toyama, Tadashi, Tanaka, Junko, Kanto, Tatsuya

“…Background Hepatitis countermeasures are being promoted by governments in Japan. We aimed to develop performance indicators (PIs) to assess the process and…”
Get full text

Structural and dynamic insights into the activation of the μ-opioid receptor by an allosteric modulator by Kaneko, Shun, Imai, Shunsuke, Uchikubo-Kamo, Tomomi, Hisano, Tamao, Asao, Nobuaki, Shirouzu, Mikako, Shimada, Ichio

“…G-protein-coupled receptors (GPCRs) play pivotal roles in various physiological processes. These receptors are activated to different extents by diverse…”
Get full text

Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease by Tamaki, Nobuharu, Kurosaki, Masayuki, Takahashi, Yuka, Itakura, Yoshie, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Sekiguchi, Shuhei, Hayakawa, Yuka, Osawa, Leona, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Yasui, Yutaka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Itakura, Jun, Izumi, Namiki

“…Background and Aim The association between liver fibrosis, fatty liver, and cardiovascular disease (CVD) risk is unknown. Hence, this study aimed to…”
Get full text

The dynamics of quantitative SARS‐CoV‐2 antispike IgG response to BNT162b2 vaccination by Kaneko, Shun, Kurosaki, Masayuki, Sugiyama, Toru, Takahashi, Yuka, Yamaguchi, Yoshimi, Nagasawa, Masayuki, Izumi, Namiki

“…Vaccination for SARS‐CoV‐2 is necessary to overcome coronavirus disease 2019 (COVID‐19). However, the time‐dependent vaccine‐induced immune response is not…”
Get full text

Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease by Tamaki, Nobuharu, Higuchi, Mayu, Kurosaki, Masayuki, Loomba, Rohit, Izumi, Namiki, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Sekiguchi, Shuhei, Hayakawa, Yuka, Osawa, Leona, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Yasui, Yutaka, Takahashi, Yuka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Itakura, Jun

“…Nonalcoholic fatty liver disease (NAFLD) has affected more than one-fourth of the global population, thus emerging as a worldwide health and economic burden.1…”
Get full text

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma by Kirino, Sakura, Tsuchiya, Kaoru, Kurosaki, Masayuki, Kaneko, Shun, Inada, Kento, Yamashita, Koji, Osawa, Leona, Hayakawa, Yuka, Sekiguchi, Shuhei, Okada, Mao, Wang, Wan, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Tamaki, Nobuharu, Yasui, Yutaka, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Asahina, Yasuhiro, Izumi, Namiki

“…Lenvatinib is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), but the effect of dose modification on its efficacy is unclear…”
Get full text

Impact of antiviral therapy for disease progression and non‐invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis by Kaneko, Shun, Kurosaki, Masayuki, Kurisu, Akemi, Akita, Tomoyuki, Tanaka, Junko, Kanto, Tatsuya

“…Background/aim Antiviral therapy advancements resulted in an era in which eradication of hepatitis C has become a goal, however, there are few reports on the…”
Get full text

Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate by Kaneko, Shun, Kurosaki, Masayuki, Tamaki, Nobuharu, Itakura, Jun, Hayashi, Tsuguru, Kirino, Sakura, Osawa, Leona, Watakabe, Keiya, Okada, Mao, Wang, Wan, Shimizu, Takao, Higuchi, Mayu, Takaura, Kenta, Yasui, Yutaka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Takahashi, Yuka, Watanabe, Mamoru, Izumi, Namiki

“…Background and Aim Tenofovir alafenamide (TAF) is a new prodrug of tenofovir, enabling treatment of patients with hepatitis B virus (HBV) infection at a lower…”
Get full text

Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis by Kaneko, Shun, Tsuchiya, Kaoru, Yasui, Yutaka, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Osawa, Leona, Hayakawa, Yuka, Sekiguchi, Shuhei, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Tamaki, Nobuharu, Takeguchi, Takaya, Takeguchi, Yuko, Nagano, Takuya, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Himeno, Yoshiro, Hoshi, Akihiko, Kurosaki, Masayuki, Izumi, Namiki

“…Aim Tyrosine kinase inhibitor (TKI) therapy resulted in better prognosis for patients with hepatocellular carcinoma (HCC). However, some cases with Barcelona…”
Get full text

Analysis of prognosis and background liver disease in non-advanced hepatocellular carcinoma in two decades by Kaneko, Shun, Asahina, Yasuhiro, Murakawa, Miyako, Azuma, Seishin, Inada, Kento, Mochida, Tomohiro, Watakabe, Keiya, Shimizu, Taro, Tsuchiya, Jun, Miyoshi, Masato, Kawai-Kitahata, Fukiko, Nitta, Sayuri, Takahashi, Marie, Fujioka, Tomoyuki, Kishino, Mitsuhiro, Anzai, Tatsuhiko, Kakinuma, Sei, Nakagawa, Mina, Okamoto, Ryuichi

“…Antiviral hepatitis and systemic therapies for hepatocellular carcinoma (HCC) remarkably progressed in the recent 10 years. This study aimed to reveal the…”
Get full text

Liver injury with COVID-19 based on gastrointestinal symptoms and pneumonia severity by Kaneko, Shun, Kurosaki, Masayuki, Nagata, Kaoru, Taki, Reiko, Ueda, Ken, Hanada, Satoko, Takayama, Koji, Suzaki, Shinichiro, Harada, Naoshige, Sugiyama, Toru, Nagasawa, Masayuki, Izumi, Namiki

“…The coronavirus disease 2019 (COVID-19) had become a big threat worldwide. Liver injury is not uncommon in patients with COVID-19, and clarifying its…”
Get full text

LIM homeobox 2 promotes interaction between human iPS-derived hepatic progenitors and iPS-derived hepatic stellate-like cells by Miyoshi, Masato, Kakinuma, Sei, Kamiya, Akihide, Tsunoda, Tomoyuki, Tsuchiya, Jun, Sato, Ayako, Kaneko, Shun, Nitta, Sayuri, Kawai-Kitahata, Fukiko, Murakawa, Miyako, Itsui, Yasuhiro, Nakagawa, Mina, Azuma, Seishin, Nakauchi, Hiromitsu, Asahina, Yasuhiro, Watanabe, Mamoru

“…Human induced pluripotent stem (iPS) cells can differentiate into hepatocyte lineages, although the phenotype of the differentiated cells is immature compared…”
Get full text

Prognosis of intrahepatic cholangiocarcinoma stratified by albumin–bilirubin grade by Kaneko, Shun, Kurosaki, Masayuki, Tsuchiya, Kaoru, Yasui, Yutaka, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Osawa, Leona, Hayakawa, Yuka, Sekiguchi, Shuhei, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Tamaki, Nobuharu, Itakura, Jun, Takahashi, Yuka, Nakanishi, Hiroyuki, Asano, Daisuke, Irie, Takumi, Kawachi, Yasuyuki, Izumi, Namiki

“…Aim Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy. However, the characteristics and prognosis of ICC is not well known. This study…”
Get full text

Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features by Kawai-Kitahata, Fukiko, Asahina, Yasuhiro, Tanaka, Shinji, Kakinuma, Sei, Murakawa, Miyako, Nitta, Sayuri, Watanabe, Takako, Otani, Satoshi, Taniguchi, Miki, Goto, Fumio, Nagata, Hiroko, Kaneko, Shun, Tasaka-Fujita, Megumi, Nishimura-Sakurai, Yuki, Azuma, Seishin, Itsui, Yasuhiro, Nakagawa, Mina, Tanabe, Minoru, Takano, Shinichi, Fukasawa, Mitsuharu, Sakamoto, Minoru, Maekawa, Shinya, Enomoto, Nobuyuki, Watanabe, Mamoru

“…Background and Aims Genetic alterations in specific genes are critical events in carcinogenesis and hepatocellular carcinoma (HCC) progression. However, the…”
Get full text

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy by Hayakawa, Yuka, Tamaki, Nobuharu, Nakanishi, Hiroyuki, Kurosaki, Masayuki, Tanaka, Yuki, Inada, Kento, Ishido, Shun, Kirino, Sakura, Yamashita, Koji, Nobusawa, Tsubasa, Matsumoto, Hiroaki, Kakegawa, Tatsuya, Higuchi, Mayu, Takaura, Kenta, Tanaka, Shohei, Maeyashiki, Chiaki, Kaneko, Shun, Yasui, Yutaka, Takahashi, Yuka, Tsuchiya, Kaoru, Okamoto, Ryuichi, Izumi, Namiki

“…Objective Rifaximin is used to treat hepatic encephalopathy. However, whether or not rifaximin and lactulose combination therapy can enhance the treatment…”
Get full text

Hepatitis B core‐related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen‐negative chronic hepatitis B patients by Kaneko, Shun, Kurosaki, Masayuki, Inada, Kento, Kirino, Sakura, Hayakawa, Yuka, Yamashita, Koji, Osawa, Leona, Sekiguchi, Shuhei, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Tamaki, Nobuharu, Yasui, Yutaka, Itakura, Jun, Takahashi, Yuka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Izumi, Namiki

“…Background and Aim The serum hepatitis B core‐related antigen (HBcrAg) is considered a surrogate marker of the amount and activity of intrahepatic covalently…”
Get full text

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy by Takaura, Kenta, Kurosaki, Masayuki, Inada, Kento, Kirino, Sakura, Yamashita, Kouji, Muto, Tomohiro, Osawa, Leona, Sekiguchi, Shuhei, Hayakawa, Yuka, Higuchi, Mayu, Kaneko, Shun, Maeyashiki, Chiaki, Tamaki, Nobuharu, Yasui, Yutaka, Itakura, Jun, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Takahashi, Yuka, Izumi, Namiki

“…The long-term prognosis of hepatocellular carcinoma (HCC) treated at a very-early-stage (the Barcelona Clinical Liver Cancer (BCLC) classification stage 0) was…”
Get full text

Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B by Kaneko, Shun, Kurosaki, Masayuki, Mashiba, Toshie, Marusawa, Hiroyuki, Kondo, Masahiko, Kojima, Yuji, Uchida, Yasushi, Fujii, Hideki, Akahane, Takehiro, Yagisawa, Hitoshi, Kusakabe, Atsunori, Kobashi, Haruhiko, Abe, Takehiko, Yoshida, Hideo, Ogawa, Chikara, Furuta, Koichiro, Tamaki, Nobuharu, Tsuji, Keiji, Matsushita, Tomomichi, Izumi, Namiki

“…Nucleos(t)ide analogs (NAs) cannot completely suppress the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed…”
Get full text

Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease by Tamaki, Nobuharu, Higuchi, Mayu, Kurosaki, Masayuki, Kirino, Sakura, Osawa, Leona, Watakabe, Keiya, Wang, Wan, Okada, Mao, Shimizu, Takao, Takaura, Kenta, Takada, Hitomi, Kaneko, Shun, Yasui, Yutaka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Enomoto, Nobuyuki, Izumi, Namiki

“…The assessment of liver fibrosis is essential because it correlates with mortality risk in nonalcoholic fatty liver disease (NAFLD). This study aims to examine…”
Get full text